IPO - Shuttle Pharmaceuticals Holdings, Inc.

Form Type: CORRESP

Filing Date: 2025-03-06

Corporate Action: Ipo

Type: New

Accession Number: 000149315225009317

Filing Summary: Shuttle Pharmaceuticals Holdings, Inc. requests acceleration of the effective date for its registration statement on Form S-1 (File No. 333-284889). The company seeks to have the registration become effective on March 7, 2025, at 4:30 PM Eastern Time. The request is made pursuant to Rule 461 of the Securities Act of 1933. The company has also authorized its legal counsel, Megan J. Penick of Dorsey & Whitney LLP, to communicate this request to the SEC staff on its behalf.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-03-06

Corporate Action: Ipo

Type: New

Accession Number: 000149315225009323

Filing Summary: Shuttle Pharmaceuticals Holdings, Inc. has filed a request for the acceleration of the effective date of its Registration Statement on Form S-1, allowing it to become effective on March 7, 2025, at 4:30 PM Eastern Time. This request is being submitted by WestPark Capital, Inc., representing the underwriters for the offering. The document outlines compliance with relevant rules and regulations, ensuring that an adequate distribution of the preliminary prospectus will be made to participating dealers and underwriters. It also confirms adherence to regulatory requirements under the Securities Act and Securities Exchange Act.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-03-05

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225009106

Filing Summary: Shuttle Pharmaceuticals Holdings, Inc. filed an amendment to its registration statement under the Securities Act of 1933 to offer up to 10,000,000 shares of common stock and pre-funded warrants, with the public offering price for each share or warrant expected to be set at $0.60. The company is in the process of completing a public offering, detailing their proprietary technologies aimed at developing innovative cancer therapies. Shuttle Pharma has received FDA approval to commence a Phase II clinical study of its lead product candidate, Ropidoxuridine (IPdR), a radiation sensitizer for glioblastoma, demonstrating its drug bioavailability during a previously completed Phase I trial. The filing also reveals operational and business strategies aimed at addressing unmet needs in cancer treatment with specific product pipeline details including various candidate therapies such as SP-2-225 and the PC-RAD Test, aimed at enhancing patient responses to radiation therapy. The document serves to update investors on the status of this offering intended to raise proceeds for funding future clinical studies and operational costs, highlighting significant risk factors and the evolving context of the biotechnology industry, which can influence their market position and investor appeal.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-02-13

Corporate Action: Ipo

Type: New

Accession Number: 000149315225006202

Filing Summary: Shuttle Pharmaceuticals Holdings, Inc. filed a Form S-1 on February 13, 2025, indicating its intent to conduct an initial public offering (IPO). The filing includes information about the proposed use of proceeds, details on the company's business operations, and financial statements for potential investors. The filing reflects the company's strategy to expand its market presence and enhance liquidity by offering shares to the public. The document outlines the company's financial condition, including revenue streams, management analysis, and risk factors associated with the business. Additionally, it provides insights into the competitive landscape and the anticipated market response to its securities offering. The application reinforces Shuttle Pharmaceuticals' commitment to growth and advancing its product pipeline, culminating in the upcoming market entry as a public entity.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-01-21

Corporate Action: Ipo

Type: New

Accession Number: 000149315225002991

Filing Summary: Shuttle Pharmaceuticals Holdings, Inc. requested an acceleration of the effective date for its registration statement on Form S-1 (File No. 333-284286) to become effective on January 23, 2025, at 5:00 PM Eastern Time. This request is pursuant to Rule 461 under the Securities Act of 1933. The company has authorized Megan J. Penick, Esq. from Dorsey & Whitney LLP to make the request on its behalf.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-15

Corporate Action: Ipo

Type: New

Accession Number: 000149315225002253

Filing Summary: Shuttle Pharmaceuticals Holdings, Inc. filed Form S-1 for the registration of securities in connection with its initial public offering (IPO). The company is seeking to raise capital to finance its ongoing research and development activities, expand its clinical trials, and bolster its operational capabilities. The filing outlines the planned use of proceeds from the offering, key financial metrics, and descriptions of the company’s current product pipeline and market strategy. It also discusses potential risks associated with the business as well as regulatory hurdles faced in the pharmaceutical industry.

Document Link: View Document